It’s my great honor to write the editorial for the pivotal MATTERHORN study @NEJM@YJanjigianMD@ASCO More global collaboration is needed to further improve outcomes for our patients with gastric/GEJ cancer.@OncoAlert@oncodaily
https://t.co/ZhCzZdCFq4
MATTERHORN: Phase III study of durvalumab + FLOT in resectable G / GEJ adenocarcinoma
#ESMO25#ESMOAmbassadors
👉 pCR: 16%, MPR: 26%, any: 87%
👉 OS: HR: 0.78; 36-mo OS: 68 vs 61%
🧐OS improved independent of TAP, better in responders > new SOC
@myesmo
We have seen the mountain ⛰️ top!
MATTERHORN OS #ESMO25
OS continues to ⬆️over time (~7% 3y)
Benefit independent of PD-L1
Enough now to adopt as SOC?
#ESMOAmbassadors